Beta-lactam antibiotics in combination with novel β-lactamase inhibitors – an alternative therapy for infections caused by multidrug-resistant bacteria

1 Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. New β-lactam-β-lactamase inhibitor combinations. Clin Microbiol Rev 2020;34(1):e00115-20. Search in Google Scholar

2 Yahav D, Giske CG, Gramatniece A, Abodakpi H, Tam VH, Leibovici L. Erratum for Yahav et al., “New β-lactam-β-lactamase inhibitor combinations”. Clin Microbiol Rev 2021;34(2):e00021-21. Search in Google Scholar

3 Novelli A, Del Giacomo P, Rossolini GM, Tumbarello M. Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination. Expert Rev Anti Infect Ther 2020;18(7):643-55. Search in Google Scholar

4 Patel TS, Pogue JM, Mills JP, Kaye KS. Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria. Future Microbiol 2018;13(9):971-83. Search in Google Scholar

5 Mansour H, Ouweini AEL, Chahine EB, Karaoui LR. Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination. Am J Health Syst Pharm 2021;78(8):674-83. Search in Google Scholar

6 Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, et al. Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-β-lactamase inhibitor combinations. Drugs 2018;78(1):65-98. Search in Google Scholar

7 Bhagunde P, Zhang Z, Racine F, Carr D, Wu J, Young K, et al. A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam. Int J Infect Dis 2019;89:55-61. Search in Google Scholar

8 Ghazi IM, El Nekidy WS, Sood A, Dulku A, Patel R, Patel K, et al. Y-site administration of imipenem/cilastatin/relebactam with common intravenous medications. Clin Ther 2020;42(3):475-85. Search in Google Scholar

9 Soriano A, Carmeli Y, Omrani AS, Moore LSP, Tawadrous M, Irani P. Ceftazidime-avibactam for the treatment of serious gram-negative infections with limited treatment options: a systematic literature review. Infect Dis Ther 2021;10(4):1989-2034. Search in Google Scholar

10 Hayden DA, White BP, Bennett KK. Review of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem/cilastatin-relebactam to target Klebsiella pneumoniae carbapenemase-producing Enterobacterales. J Pharm Technol 2020;36(5):202-10. Search in Google Scholar

11 European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters, ver. 13.0. Vaxjo, Sweden: EUCAST; 2023. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_13.0_Breakpoint_Tables.pdf (1.10.2023). Search in Google Scholar

12 Brauncajs M, Bielec F, Macieja A, Pastuszak-Lewandoska D. Carbapenemresistant Gram-negative fermenting and non-fermenting rods isolated from hospital patients in Poland – what are they susceptible to? Biomedicines 2022;10(12):3049. Search in Google Scholar

13 Gaibani P, Re MC, Campoli C, Viale PL, Ambretti S. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization. Clin Microbiol Infect 2020;26(4):516.e1-4. Search in Google Scholar

14 Swaminathan S, Routray A, Mane A. Early and appropriate use of ceftazidime-avibactam in the management of multidrug-resistant Gram-negative bacterial infections in the Indian scenario. Cureus 2022;14(8):e28283. Search in Google Scholar

15 Zalas-Więcek P, Prażyńska M, Pojnar Ł, Pałka A, Żabicka D, Orczykowska-Kotyna M, et al. Ceftazidime/avibactam and other commonly used antibiotics activity against Enterobacterales and Pseudomonas aeruginosa isolated in Poland in 2015–2019. Infect Drug Resist 2022;15:1289-304. Search in Google Scholar

16 Bonnin RA, Bernabeu S, Emeraud C, Naas T, Girlich D, Jousset AB, et al. In vitro activity of imipenem-relebactam, meropenem-vaborbactam, ceftazidime-avibactam and comparators on carbapenem-resistant non-carbapenemase-producing Enterobacterales. Antibiotics (Basel) 2023;12(1):102. Search in Google Scholar

17 Wang Y, Wang J, Wang R, Cai Y. Resistance to ceftazidime-avibactam and underlying mechanisms. J Glob Antimicrob Resist 2020;22:18-27. Search in Google Scholar

18 Gaibani P, Lombardo D, Bussini L, Bovo F, Munari B, Giannella M, et al. Epidemiology of meropenem/vaborbactam resistance in KPC-producing Klebsiella pneumoniae causing bloodstream infections in northern Italy, 2018. Antibiotics (Basel) 2021;10(5):536. Search in Google Scholar

19 Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF. In vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae. Antimicrob Agents Chemother 2017;62(1):e01904-17. Search in Google Scholar

20 Nordmann P, Bouvier M, Poirel L. Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland. Eur J Clin Microbiol Infect Dis 2023;42(9):1145-52. Search in Google Scholar

21 Sader HS, Mendes RE, Duncan L, Kimbrough JH, Carvalhaes CG, Castanheira M. Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018–2022). Diagn Microbiol Infect Dis. 2023;106(2):115945. Search in Google Scholar

22 Castanheira M, Huband MD, Mendes RE, Flamm RK. Meropenem-vaborbactam tested against contemporary gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother 2017;61(9):e00567-17. Search in Google Scholar